Federica Buggin

Early-onset BRAF -mutant metastatic colorectal cancer: A distinct clinical and molecular signature.

Andrea Pretta, Gaia Rebecchi, Federica Marmorino, Giulia Maddalena et autres

e15533 Background: BRAF V600E–mutant metastatic colorectal cancer (mCRC) is associated with poor prognosis and marked biological heterogeneity. Age at disease onset has emerged as a clinically relevant factor in colorectal cancer, but its influence on the biology of BRAF-mutant mCRC remains unclear. …

it (code pays fourni par la source)

PAXG versus (m)FOLFIRINOX as first-Line therapy for unresectable locally advanced or metastatic pancreatic cancer: A real-world, propensity-weighted analysis.

Sara Sperotto, Giacomo Di Paolo, Federico Nichetti, Mario Domenico Rizzato et autres

e16401 Background: The PACT-21 (CASSANDRA) study recently demonstrated an event-free survival benefit with PAXG (cisplatin, nab-paclitaxel, capecitabine and gemcitabine) over modified FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan and oxaliplatin) as neoadjuvant regimen in patients (pts) with early-stage pancreatic cancer (PDAC). A head-to-head comparison …

it (code pays fourni par la source)

Ultra–early-onset metastatic colorectal cancer (<35 years): RAS-driven, APC/TP53-depleted, TMB-low molecular features in a real-world analysis of 2,392 patients.

Andrea Pretta, Giulia Maddalena, Gaia Rebecchi, Federica Marmorino et autres

3542 Background: Early-onset colorectal cancer (CRC, <50 years) is on the rise globally and includes a biologically heterogeneous disease. Patients diagnosed before age 35 represent the extreme of early-onset CRC, yet their clinical and genomic features remain poorly understood. We investigated whether …

it (code pays fourni par la source)

Abstract 7908: Distinct molecular and clinical aggressiveness in very early-onset colorectal cancer: Survival and genomic divergence between patients aged 30-39 vs 40-49 years

Andrea Pretta, Gaia Rebecchi, Giulia Maddalena, Federica Marmorino et autres

Abstract Background: Early-onset colorectal cancer (EO-CRC) is rising worldwide and exhibits clinical heterogeneity. Patients under 40 may constitute a biologically distinct subgroup within EO-CRC. We investigated whether “very early-onset” colorectal cancer (VEO-CRC, ages 30-39) exhibits specific clinical and genomic features compared with …

it, br (code pays fourni par la source)

218eP Clinical and molecular features of small bowel adenocarcinoma: A single-center study

Maria Caterina De Grandis, Krisida Cerma, R. Intini, Federica Buggin et autres

it (code pays fourni par la source)

Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO Foundation

Sara Lonardi, Cosimo Rasola, Riccardo Lobefaro, Daniele Rossini et autres

PURPOSE To verify whether both doublet chemotherapy with a modified schedule of fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) and monochemotherapy with fluorouracil plus leucovorin (5-FU + LV) achieve satisfactory efficacy when both regimens are combined with panitumumab (PAN) as initial treatment of elderly …

it (code pays fourni par la source)

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Michele Reni, M. Reni, E Giommoni, F C Bergamo et autres

BACKGROUND: Information about the adherence to scientific societies guidelines in the 'real-world' therapeutic management of oncological patients are lacking. This multicenter, prospective survey was aimed to improve the knowledge relative to 2017-2018 recommendations of the Italian Association of Medical Oncology (AIOM). PATIENTS …

it (code pays fourni par la source)

Prognostic value of baseline G8 geriatric assessment in a real-life population of elderly metastatic colorectal cancer patients: The Gold Study.

Giulia Maddalena, Alessandra Anna Prete, Federica Buggin, Fable Zustovich et autres

e24015 Background: Colorectal cancer (CRC) is the second most frequent malignancy in patients (pts) aged 70. Elderly patients are often excluded by clinical trials; however, improvements in quality of life and comorbidities management led to expand the access to anticancer treatments irrespectively …

it (code pays fourni par la source)

First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.

Sara Lonardi, Marta Schirripa, Federica Buggin, Lorenzo Antonuzzo et autres

4002 Background: Data on first-line treatment efficacy in elderly patients are limited. Many analyses adopt a questionable cut-off of 65 years and specific evidence with anti-EGFRs is low. FOLFOX-panitumumab (pan) is an option for RAS wild-type (wt) untreated mCRC patients. Guidelines recommend …

it (code pays fourni par la source)

A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Fotios Loupakis, Rossana Intini, Chiara Cremolini, Armando Orlandi et autres

it, be (code pays fourni par la source)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients

Francesca Battaglin, Marta Schirripa, Federica Buggin, Filippo Pietrantonio et autres

BACKGROUND: Few data are available regarding the treatment of metastatic colorectal cancer elderly patients with anti-EGFR agents in combination with chemotherapy. FOLFOX plus panitumumab is a standard first-line option for RAS wild-type metastatic colorectal cancer. Slight adjustments in chemo-dosage are commonly applied …

it (code pays fourni par la source)

Potential contribution of the study nurse to colorectal cancer (CRC) translational research

I. Rigotto, Marta Schirripa, D. Costardi, Fotios Loupakis et autres

it (code pays fourni par la source)